Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Glenn D, Crater"'
Autor:
Jill A. Ohar, Donald A. Mahler, Gabrielle N. Davis, David A. Lombardi, Edmund J. Moran, Glenn D. Crater
Publikováno v:
Canadian Respiratory Journal, Vol 2024 (2024)
Introduction. Many patients with chronic obstructive pulmonary disease (COPD) may derive inadequate benefit from dry powder inhalers (DPIs) because of suboptimal peak inspiratory flow (sPIF). Objectives. To assess the clinical burden of COPD by chara
Externí odkaz:
https://doaj.org/article/3fe1f8d771d149378c032a703727515a
Autor:
James F. Donohue, Edward Kerwin, Chris N. Barnes, Edmund J. Moran, Brett Haumann, Glenn D. Crater
Publikováno v:
BMC Pulmonary Medicine, Vol 20, Iss 1, Pp 1-10 (2020)
Abstract Background Revefenacin, a once-daily, long-acting muscarinic antagonist delivered via standard jet nebulizer, increased trough forced expiratory volume in 1 s (FEV1) in patients with moderate to very severe chronic obstructive pulmonary dise
Externí odkaz:
https://doaj.org/article/a02dc5fee0344cab954ec9e187b55225
Publikováno v:
Therapeutic Advances in Respiratory Disease, Vol 16 (2022)
Background: Data for bronchodilator deposition via nebulizers and dry powder inhalers (DPIs) in the respiratory tract of patients with chronic obstructive pulmonary disease (COPD) are limited. We used functional respiratory imaging (FRI) to determine
Externí odkaz:
https://doaj.org/article/7a0b48d4b5a9451b9d65407b0306af0a
Publikováno v:
Therapeutic Advances in Respiratory Disease, Vol 14 (2020)
Background: Combinations of a long-acting muscarinic receptor antagonist (LAMA), long-acting β-agonist (LABA), and inhaled corticosteroid (ICS) are used for patients with persistent chronic obstructive pulmonary disease (COPD) exacerbations on bronc
Externí odkaz:
https://doaj.org/article/1c2a47d957cd4efa80a10a3aa452b662
Autor:
Dennis L Kelleher, Rashmi S Mehta, Bernadette M Jean-Francois, Andrew F Preece, James Blowers, Glenn D Crater, Paul Thomas
Publikováno v:
PLoS ONE, Vol 7, Iss 12, p e50716 (2012)
Umeclidinium bromide (GSK573719; UMEC), a new long-acting muscarinic receptor antagonist (LAMA), is in development with vilanterol (GW642444; VI), a selective long-acting β(2) agonist (LABA), as a once-daily inhaled combination therapy for the treat
Externí odkaz:
https://doaj.org/article/67a39d40dcd949bb97b27ea55ef4ff4d
Publikováno v:
Chest. 158(4)
Peak inspiratory flow (PIF) has been proposed as a measure to assess a patient's ability to use dry powder inhalers (DPIs). However, robust quality criteria to determine a repeatability limit for measuring PIF are lacking.What are the repeatability l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::fc50c1c6c294c1ff9a744f63699a3f07
https://pubmed.ncbi.nlm.nih.gov/32343967
https://pubmed.ncbi.nlm.nih.gov/32343967
Publikováno v:
The American journal of managed care. 18(9)
To examine the impact of timing of maintenance treatment initiation (early vs delayed) on risk of future exacerbations and costs in chronic obstructive pulmonary disease (COPD) patients.Retrospective cohort design using data (January 1, 2003, through
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::71e5e7ad7e54753e27c7f69c032cce6c
https://pubmed.ncbi.nlm.nih.gov/23009332
https://pubmed.ncbi.nlm.nih.gov/23009332
Autor:
Glenn D. Crater
Publikováno v:
Chest. 124:1175-1176
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b2cfca7df0bdc05ad438a43abad8ff8f
https://doi.org/10.1378/chest.124.3.1175
https://doi.org/10.1378/chest.124.3.1175
Autor:
Dianne O Dell, Glenn D. Crater, Amanda Emmett, Nicola A. Hanania, Michael J. Cicale, Dennis E. Niewoehner
Publikováno v:
Chest. 138:867A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::92b89408145788f95b944e2dfe0de1c2
https://doi.org/10.1378/chest.10278
https://doi.org/10.1378/chest.10278